DURECT Corporation (NASDAQ:DRRX) down by 42.13%, Affymax Inc. (NASDAQ:AFFY)

Posted by Nathan Alexander May 10, 2013 0 Comment 1798 views


Hartford, CT 05/10/2013 (GDPInsider) – DURECT Corporation (NASDAQ:DRRX) is down by about 42.13% after hitting a high of $0.97 during the day, and is now hovering at $0.920. The traded volumes during the day were higher than the average volume of 0.595 million, and the current trading volume is more than 3.65 million. The beta of the stock is 1.34. With a book value per share of about 0.35 the price to book value ratio of the DURECT is close to 4.54 which is weak. The investors can get a clue about the stock’s performance from the investors holding in the company’s share which is close to 0.03% as of May 10, at the same time the institutional investors are holding about 48.29% in the company’s stock. The net profit margin over the trailing twelve months of the company is close to 30.53%. The analysts’ are expecting a price of $3.00 for the stock, thus we can expect the stock to rise further expect.

Pain Therapeutics, Inc. (NASDAQ:PTIE) said its marketing partner Pfizer Inc. (NYSE:PFE), for painkiller Remoxy, has not yet decided on seeking a regulatory approval for its drug. DURECT provides the technology which is used in Remoxy.

How Should Investors Trade DRRX Now? Get key and important information right here.

Affymax, Inc. (NASDAQ:AFFY) is down by about 26.90% after hitting a high of $1.52 during the day, and is now hovering at $1.33. The traded volumes during the day were higher than the average volume of 5.80 million, and the current trading volume is more than 12.72 million. The beta of the stock is 1.00. With a book value per share of about 0.22 the price to book value ratio of the Affymax is close to 8.26 which is quite decent. The investors can get a clue about the stock’s performance from the investors holding in the company’s share which is close to 0.54% as of May 10, at the same time the institutional investors are holding about 83.81% in the company’s stock. The net profit margin over the trailing twelve months of the company is close to -98.98%. The analysts’ are expecting a price of $4.75 for the stock, thus we can expect the stock to rise further expect.

The company said that it has incurred significant operating losses since its inception and is taking stpes to decrease its outstanding obligations to the third parties. The company said that it is in the process of exploring various strategic alternatives, which includes corporate merger of sale of the company or is assets. It is also looking for any restructuring actives, bankruptcy proceedings or wind-down of operations. The accumulated deficit was about $570.4 million as of March 31

How Should Investors Trade AFFY Now? Get the latest trends and data here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment